Quince Therapeutics, Inc. cash flow to debt ratio of -224.27% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Quince Therapeutics, Inc.'s free cash flow has decreased 29.90% from $-32.16M last year to $-41.78M, signaling decreasing performance

Quince Therapeutics, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Quince Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.49 last year to 0.03 today, signaling strengthened financials

Quince Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Quince Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Quince Therapeutics, Inc. has insufficient data to evaluate this check.

Quince Therapeutics, Inc.'s short-term liabilities of $43.23M exceed its short-term assets of $22.90M, signaling financial risk

Quince Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Quince Therapeutics, Inc.'s return on equity of 1.82K%, is higher than 15.00%, indicating good performance

Quince Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Quince Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Quince Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Quince Therapeutics, Inc. has negative free cash flow, indicating cash burn

Quince Therapeutics, Inc.'s yearly earnings has decreased 47.78% since last year from $-56.83M to $-83.98M, signaling decreasing performance

Quince Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -280.90% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Quince Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Quince Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Quince Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Quince Therapeutics, Inc. has insufficient data to evaluate this check.

Quince Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Quince Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Quince Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Quince Therapeutics, Inc. has insufficient data to evaluate this check.

Quince Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Quince Therapeutics, Inc. has a price-to-book ratio of 0.49x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Quince Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue